Tarek Hassanein
Overview
Explore the profile of Tarek Hassanein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
4574
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Honarvar M, Lobo J, Schneider C, Wolfe N, Gawrieh S, Loomba R, et al.
Ultrasound Med Biol
. 2024 Sep;
50(12):1812-1820.
PMID: 39244483
Objective: As metabolic dysfunction-associated steatotic liver disease (MASLD) becomes more prevalent worldwide, it is imperative to create more accurate technologies that make it easy to assess the liver in a...
2.
Hassanein T, Keaveny A, Mantry P, Smith A, McRae M, Kittelson J, et al.
Aliment Pharmacol Ther
. 2024 Jun;
60(3):405-406.
PMID: 38924551
No abstract available.
3.
Hassanein T, Keaveny A, Mantry P, Smith A, McRae M, Kittelson J, et al.
Aliment Pharmacol Ther
. 2024 May;
60(2):246-256.
PMID: 38778481
Background: The quantitative HepQuant SHUNT test of liver function and physiology generates a disease severity index (DSI) that correlates with risk for clinical complications, such as large oesophageal varices (LEVs)....
4.
Loomba R, Ramji A, Hassanein T, Yoshida E, Pang E, Schneider C, et al.
Hepatol Commun
. 2024 Mar;
8(4).
PMID: 38517204
Background: As the prevalence of metabolic dysfunction-associated steatotic liver disease increases, it is imperative to have noninvasive alternatives to liver biopsy. Velacur offers a non-invasive, point-of-care ultrasound-based method for the...
5.
Yuen M, Fung S, Ma X, Nguyen T, Hassanein T, Hann H, et al.
JHEP Rep
. 2024 Mar;
6(4):100999.
PMID: 38510983
Background & Aims: The investigational first-generation core inhibitor vebicorvir (VBR) demonstrated safety and antiviral activity over 24 weeks in two phase IIa studies in patients with chronic HBV infection. In...
6.
Hassanein T, McClain C, Vatsalya V, Stein L, Flamm S, Martin P, et al.
Am J Gastroenterol
. 2023 Apr;
119(1):107-115.
PMID: 37011138
Introduction: This study is to evaluate the safety and pharmacokinetics (PK) of larsucosterol (DUR-928 or 25HC3S) in subjects with alcohol-associated hepatitis (AH), a devastating acute illness without US Food and...
7.
Feld J, Lawitz E, Nguyen T, Lalezari J, Hassanein T, Martin P, et al.
Antivir Ther
. 2022 Nov;
27(6):13596535221127848.
PMID: 36382358
Background: Chronic hepatitis B (CHB) remains a major cause of morbidity and mortality. EDP-514 is a potent core inhibitor of hepatitis B virus (HBV) that reduces viral load reduction in...
8.
Saliba F, Banares R, Larsen F, Wilmer A, Pares A, Mitzner S, et al.
Intensive Care Med
. 2022 Sep;
48(10):1352-1367.
PMID: 36066598
The present narrative review on albumin dialysis provides evidence-based and expert opinion guidelines for clinicians caring for adult patients with different types of liver failure. The review was prepared by...
9.
Hassanein T, Tai D, Liu C, Box T, Tong M, Rossaro L, et al.
Evid Based Complement Alternat Med
. 2022 Jul;
2022:4494099.
PMID: 35873630
Background: Hepatitis C virus (HCV) is a common cause of progressive hepatic fibrosis, cirrhosis, and hepatocellular carcinoma worldwide. Despite the availability of effective direct-acting antivirals, patients often have significant hepatic...
10.
Sulkowski M, Agarwal K, Ma X, Nguyen T, Schiff E, Hann H, et al.
J Hepatol
. 2022 Jun;
77(5):1265-1275.
PMID: 35697332
Background & Aims: Nucleos(t)ide reverse transcriptase inhibitors do not completely suppress HBV DNA in chronic HBV infection (cHBV). Vebicorvir (VBR) is an investigational core inhibitor that interferes with multiple aspects...